I had gathered that the driving force behind PolyM was a genius but a horse's rear to work with and he pissed off every pharma company he worked with. Then they had the B Ph2 trial which, like you stated and I agree, mgt misinterpreted the results and didn't realize the full potential of B. But what is quirky is that they then presented the data in Germany that showed how robust were the results for B in the trials but it appears the big US pharmas somehow missed out on this presentation and outlook for B and that is why they didn't bid for it out of bankruptcy.
I think PolyM just panicked or the genius in charge, who must be a very rich man without PolyM, just said enough is enough and I am out of here and took his ball and went home. I concur fully w/ PepsiM that it was a classic case of PolyMedix management screwing up the business from start to finish and the science of the products had nothing to do with it.
If nothing else, they could have sold off packages of 5 of their 70 products in the pipeline in numerous sales (say 5 sales of 5 each and each packet costs $X MM to acquire) to some large pharma or other to get revenue to carry them thru any shortages. PolyM had the reputation as a great small molecule development company, someone would have paid for their products.
AI
Market Data 
Markets 
